Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

NOVO NORDISK : Buy rating from JP Morgan

10/14/2020 | 03:40am EST

In his latest research note, analyst Richard Vosser confirms his positive recommendation. The broker JP Morgan is keeping its Buy rating. The target price remains unchanged at DKK 480.


© MarketScreener with dpa-AFX Analyser 2020
All news about NOVO NORDISK A/S
12/04NOVO NORDISK A/S : Files FDA New Drug Application for Obesity Drug
DJ
12/04NOVO NORDISK A/S : files for US FDA regulatory approval of once-weekly semagluti..
AQ
12/01NOVO NORDISK A/S : - Company announcements, trading in own shares
AQ
12/01NOVO NORDISK A/S : ESG presentation ()
PU
12/01NOVO NORDISK : Gets a Buy rating from JP Morgan
MD
11/30Weight-Loss Firm Noom Names First CFO
DJ
11/23NOVO NORDISK A/S : – Share repurchase programme
AQ
11/20India's Gland Pharma jumps 23% in market debut
RE
11/18NOVO NORDISK A/S : - Once-weekly semaglutide 2.0 mg demonstrates superior reduct..
AQ
11/18NOVO NORDISK A/S : Experts Urge Govt to Subsidise Cost of Diabetes Management, T..
AQ
More news
Financials
Sales 2020 127 B 20 754 M 20 754 M
Net income 2020 42 166 M 6 869 M 6 869 M
Net cash 2020 8 472 M 1 380 M 1 380 M
P/E ratio 2020 22,9x
Yield 2020 2,17%
Capitalization 961 B 157 B 157 B
EV / Sales 2020 7,47x
EV / Sales 2021 7,02x
Nbr of Employees 44 326
Free-Float 75,1%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Average target price 439,69 DKK
Last Close Price 415,10 DKK
Spread / Highest target 31,3%
Spread / Average Target 5,92%
Spread / Lowest Target -30,1%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S7.36%156 651
JOHNSON & JOHNSON3.02%395 592
ROCHE HOLDING AG-3.74%290 107
PFIZER, INC.8.67%224 226
MERCK & CO., INC.-9.91%207 311
NOVARTIS AG-11.64%207 247